Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jenna Pelc

Nurse Practitioner, Family Springfield, IL Nurse Practitioner

NPI 1730508300 CMS profile 11092673

800 N 1St St, Springfield, IL 62702

Open in the dashboard

General payments

$52,626

896 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jenna Pelc of Springfield, IL is reported in the CMS Open Payments database as having received $52,626 across 896 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,551 155
2024 General $5,535 183
2023 General $6,685 198
2022 General $15,193 156
2021 General $22,663 204

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jenna Pelc
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jenna Pelc were reported at $2,551. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jenna Pelc Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $22,663 $124 $35–$379 $132
2022 $15,193 $141 $44–$430 $149
2023 $6,685 $154 $49–$476 $160
2024 $5,535 $165 $51–$504 $164
2025 $2,551 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $42,234 313 payments
  2. Abbott Laboratories $1,566 20 payments
  3. Teva Pharmaceuticals USA, Inc. $1,398 99 payments
  4. Allergan Inc. $886 9 payments
  5. Celgene Corporation $637 78 payments
  6. Biohaven Pharmaceuticals, Inc. $624 67 payments
  7. Lundbeck LLC $606 29 payments
  8. Pfizer Inc. $503 62 payments
  9. Mallinckrodt Hospital Products Inc. $493 17 payments
  10. Amgen Inc. $378 17 payments
  11. Other $3,301 185 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $37,663 31 payments
  2. Food and Beverage $12,160 838 payments
  3. Travel and Lodging $2,605 23 payments
  4. Education $198 4 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $35,775 238 payments
  2. QULIPTA $11,586 150 payments
  3. INFINITY $1,551 19 payments
  4. NURTEC ODT Primary Care $961 99 payments
  5. Austedo XR $648 48 payments
  6. ZEPOSIA $624 74 payments
  7. VYEPTI $545 25 payments
  8. NURTEC ODT Pain $503 62 payments
  9. AUSTEDO $502 35 payments
  10. ACTHAR $493 17 payments
  11. Other $4,612 269 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

1,738

Median for Nurse Practitioner: 389

Drug cost

$507,641

Median for Nurse Practitioner: $21,885

Branded share of claims

25.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Octagam Immun Globg(Igg)/Malt/Iga Ov50 Brand 24 $170,815
Nurtec Odt Rimegepant Sulfate Brand 42 $70,805
Nuplazid Pimavanserin Tartrate Brand 13 $66,158
Ubrelvy Ubrogepant Brand 34 $44,632
Topamax Topiramate Brand 11 $29,872
Lamictal Lamotrigine Brand 23 $27,258
Emgality Pen Galcanezumab-Gnlm Brand 27 $25,977
Aimovig Autoinjector Erenumab-Aooe Brand 19 $18,638
Rexulti Brexpiprazole Brand 16 $13,079
Carbamazepine Er Carbamazepine Brand 42 $7,494

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$415,052

Of which drugs: $383,113

Medicare patients

222

Average age 72

Services billed

20,505

135 women, 87 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 37%
Depression 37%
Diabetes 31%
Alzheimer's or dementia 27%
Atrial fibrillation 22%
Chronic kidney disease 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 12 6,950 $31,559

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
QULIPTA
  • AbbVie, Inc. $2,488
$2,488 — —
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $410
$410 — —
UBRELVY
  • AbbVie, Inc. $375
$375 34 —
ZEPOSIA
  • Celgene Corporation $225
$225 — —
ACTHAR
  • Mallinckrodt Hospital Products Inc. $156
$156 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

896 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record